Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Heron Therapeutics Are Crashing Today

By George Budwell - Feb 29, 2016 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA delays Sustol's regulatory decision yet again.

What: Shares of Heron Therapeutics (HRTX 1.19%) dropped by as much as 16.7% in early morning trading today after the company announced that the FDA has still not concluded its regulatory review of Sustol, an experimental drug indicated for chemotherapy-induced nausea.

Image source: Wikimedia Commons

So what: Sustol's review was originally supposed to wrap up by Jan. 17, 2016. However, the FDA informed the company that it needed additional time complete the drug's review last January, initially pushing the target review date back to Feb. 26. Sustol's regulatory decision has thus been delayed twice by the FDA since the start of the year. 

Now what: The market is growing increasingly concerned that these repeated delays might indicate that the FDA is about to issue its third Complete Response Letter for this much-maligned experimental drug -- despite the drug reportedly outperforming GlaxoSmithKline's (GSK 2.20%) former blockbuster Zofran in its latest pivotal-stage trial.

Although it's impossible to know why the FDA is taking so long to complete this particular review, these delays do show that the drug's approval isn't exactly a slam dunk. As such, investors might want to remain on the sidelines with this stock until this significant regulatory risk is off the table. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$3.40 (1.19%) $0.04
GSK Stock Quote
GSK
GSK
$43.69 (2.20%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.